Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
+$0.10 today
- Market cap
- $107.33M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
Volume 0.53M
Average 0.15M
FHTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Foghorn Therapeutics Inc.NASDAQ: FHTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $19.88M (cash outflow) rose 5.5% year over year, ahead of the -6.4% change in trailing-twelve-month net income. Sequentially, it fell 8.3% from the prior quarter. Over 3 fiscal years it compounded at -12.0% a year.
Context
- Net income amounted to 240.3% of revenue in FY2025, down 142.9 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$27M (-63.7%) for the fiscal year ending Dec 2026, a slowdown from the -14.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.88M-8.3% QoQ
- Last fiscal yearDec 2025
- -$74.28M-14.2% YoY
- LTMMar 2026
- -$75.32M-6.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.5% | -0.8% | -6.4 pp |
| 1 year | -14.2% | -63.7% | -49.4 pp |
| 3-year CAGR | -12.0% | -6.5% | +5.4 pp |
| 5-year CAGR | -5.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (74.28M) USD
- Year-over-year change
- +14.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (74.28M) | +14.2% |
| FY2024 | 2024-12-31 | (86.62M) | +12.0% |
| FY2023 | 2023-12-31 | (98.43M) | +9.6% |
| FY2022 | 2022-12-31 | (108.88M) | -7.5% |
| FY2021 | 2021-12-31 | (101.32M) | — |
Net Income vs competitors
How FHTX compares with its peers on the latest reported figures
- FHTX's LTM Mar 2026 net income of $75.32M is the 7th largest of the 11 companies compared; the peer median is $78.05M.
- Its year-over-year change of -6.4% is the 5th highest of 11, against a peer median of -13.0%.
- Net income amounts to 266.9% of revenue for FHTX, versus a peer median of 173.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $239.55M | +441.4% | — | 110.0% | |
| LTM Mar 2026 | $166.12M | -770.3% | +15.0% | 2895.1% | |
| LTM Mar 2026 | $97.59M | +25.7% | +50.6% | 4840.8% | |
| LTM Mar 2026 | $81.74M | -14.2% | -13.0% | 589.8% | |
| LTM Mar 2026 | $78.67M | +15.4% | — | 173.5% | |
ZURAZura Bio Limited | LTM Mar 2026 | $77.43M | +24.7% | +35.9% | — |
| LTM Mar 2026 | $75.32M | -6.4% | -12.0% | 266.9% | |
| LTM Mar 2026 | $61.98M | -35.7% | -12.4% | 89.6% | |
| LTM Mar 2026 | $54.44M | -11.9% | +3.5% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $43.51M | -23.8% | +18.7% | — |
| LTM Mar 2026 | $6.38M | -84.0% | -59.6% | 9.0% | |
| Peer median (excluding FHTX) | $78.05M | -13.0% | +9.2% | 173.5% | |
Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (101.32M) | (108.88M) | (98.43M) | (86.62M) | (74.28M) |
| Depreciation & Amortization | 3.23M | 7.9M | 3.45M | 3.12M | 3.33M |
| Deferred Income Tax | 1.41M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.38M | 0 | 16.19M | 11.89M | 10.4M |
| Change in Working Capital | 33.44M | 281.55M | (41.88M) | (32.27M) | (32.14M) |
| Accounts Receivables | (300M) | 300M | 0 | 0 | 0 |
| Inventory | (3.17M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 135K | 1.61M | 846K | (2.48M) | 481K |
| Other Working Capital | 336.48M | (20.07M) | (42.73M) | (29.79M) | (32.62M) |
| Other Non-Cash Items | 4.61M | 13.05M | 2.56M | 3.47M | 6.59M |
| Operating Cash Flow | (50.25M) | 193.61M | (118.11M) | (100.41M) | (86.1M) |
| Capital Expenditures | (3.31M) | (1.21M) | (1.22M) | (906K) | (50K) |
| Acquisitions (Net) | (39.49M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (99.98M) | (409.35M) | (73.9M) | (261.47M) | (131.25M) |
| Sales of Investments | 139.47M | 166.23M | 219.58M | 232.47M | 243.34M |
| Other Investing Activities | 39.49M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 36.17M | (244.32M) | 144.45M | (29.9M) | 112.04M |
| Debt Repayment | (21.21M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 42.21M | 1.76M | 0 | 103.4M | 1.02M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.42M | 0 | 1.78M | 2.03M | 0 |
| Financing Cash Flow | 22.42M | 1.76M | 1.78M | 105.43M | 1.02M |
| Effect of Forex Changes | 0 | 25K | 0 | 0 | 0 |
| Net Change in Cash | 8.34M | (48.92M) | 28.12M | (24.88M) | 26.96M |
| Free Cash Flow | (53.56M) | 192.4M | (119.33M) | (101.31M) | (86.15M) |
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Intrinsic Alpha fair value
Locked
Current Price
$1.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.